auto_awesome_motion View all 2 versions
organization

PFIZER

PFIZER LIMITED
Country: United Kingdom
90 Projects, page 1 of 18
  • Open Access mandate for Publications
    Funder: EC Project Code: 644056
    Overall Budget: 216,000 EURFunder Contribution: 216,000 EUR
    Partners: PFIZER, PION INC.(UK) LTD, UCPH, UCC, GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD., PARAYTEC

    The CRYDIS exchange programme will establish and support international and inter-sectoral transfer of knowledge and expertise in pharmaceutical and instrument science between several EU research institutes and industrial companies. It will also enhance understanding of the value of inter-sectoral exchange mechanisms for taking research to market. CRYDIS undertakes innovative, collaborative research on the clinically-important topic of dissolution of drug substance particles in bio-relevant media and the undesired subsequent nucleation and re-precipitation of the drug prior to its absorption. Using innovative advances in UV imaging technology, CRYDIS investigates the utility of novel dissolution assays as key tools to obtain fundamental data on the mechanism and kinetics of undesired nucleation and re-precipitation during or following dissolution, a significant problem for the pharmaceutical industry which struggles to obtain sufficient exposure to poorly soluble drug substances to ensure an effective dose is absorbed by the patient. The key technologies in this proposal offer a step change in capability and functionality, offering the potential to undertake more detailed studies of the dissolution/re-precipitation processes relevant to pharmaceutical materials. Access to this key technology and the further development of its capability offers the potential for breakthroughs in development of process understanding and of robust and widely applicable protocols. Additional value is brought to CRYDIS through close working with synergistic European networks, leveraging a greater knowledge input and impact outreach. Running parallel with the science programme, an innovation management work-package analyses effectiveness of the exchange mechanism in building a shared culture, transferring knowledge and developing understanding of processes that drive a product to market. The outcomes of this will be used to advise and drive potential future exchange activities.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101034439
    Overall Budget: 2,162,500 EURFunder Contribution: 1,000,000 EUR
    Partners: University of Vienna, MPG, AXXAM SPA, PFIZER, University of Liverpool, CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH, Leiden University, Bayer AG, UOXF

    Solute carriers (SLCs) are the largest family of membrane transporters encoded in the human genome and their role in trafficking nutrients, ions, vitamins and cofactors is vital for maintaining homeostasis in individual cells, organs and tissues. Their misfunction is associated with a variety of diseases and a small number of individual SLCs are successful drug targets. Despite their importance, SLCs remain understudied and a surprisingly large proportion is deemed “orphan” in terms of transport function. The ongoing RESOLUTE IMI consortium is working on the systematic de-orphanization of SLCs and is highly successful in creating open-access tools, high-throughput assays and omics data. This effort is focused on basic aspects of SLC biochemistry and biology and was not meant to include the medical dimension. In the REsolution program we propose here, we exploit the unique opportunity to now link the RESOLUTE knowledge to physiology and disease through human genetics. The goal is to maximize the chances that SLC transporters will become successful drug targets and use the growing amount of data becoming available on genetic variations and disease association to assign pathophysiological relevance to individual transporters. Concretely, we plan to: 1) assemble human SLC genetic information and annotate within the RESOLUTE knowledgebase; 2) study the structure-activity relationship for selected SLC variants, 3) use deep mutagenesis and artificial intelligence to develop the equivalent of a “Rosetta stone” allowing the interpretation of SLC genetic variation. This will allow us to not only contextualize SLCs, as elucidated by RESOLUTE, in the current human medical genetics landscape, but also to create an SLC prioritization rationale and a resource of the whole SLC family for the pharmaceutical industry valid for years to come.

  • Funder: EC Project Code: 223234
    Partners: QUB, KI, UZH, UCL, AMC, ULP, PFIZER, Hubert Andreas JOHN, LUNDS UNIVERSITET, University of Surrey
  • Funder: EC Project Code: 115766
    Partners: KI, ETH Zurich, UOXF, DRX, Bayer AG, Janssen (Belgium), PFIZER, UNIVERSITY OF TORONTO, The Structural Genomics Consortium, NOVARTIS...
  • Project . 2018 - 2020
    Open Access mandate for Publications and Research data
    Funder: EC Project Code: 807010
    Overall Budget: 2,140,980 EURFunder Contribution: 1,168,750 EUR
    Partners: CSL BEHRING GMBH, MHRA, AEMPS, International Health, UMC, PFIZER, Lareb, DANISH MEDICINES AGENCY, HALMED, AbbVie...

    This proposal seeks to build on the mobile application (app) functionality delivered through the original WEB-RADR project to expand access to the platform and the reach of the information contained within it. It will achieve this by making the functionality available through application programming interfaces (APIs), meaning that third party organisations will be able to embed WEB-RADR platform functionality into their own systems, applications and websites. An important component to this will be a terminology/classification mapping activity involving the three core healthcare terminology owners; MedDRA MSSO, SNOMED International and WHO. The mapping will facilitate communication between regulatory and healthcare databases by establishing mapping protocols and delivering an initial mapping between a subset of key pharmacovigilance terms. The project has established use cases and adopters for the proposed functionality through the networks established through the original WEB-RADR delivery, and has a diverse range of partners keen to utilise different aspects of the proposed solutions including regulatory authorities, health charities and system providers.